Intrathecal methylprednisolone acetate in multiple sclerosis treatment. Clinical evaluation.
Twenty-eight patients with clinically definite Multiple Sclerosis were treated with intrathecal injections of Methylprednisolone acetate, 40 mg at four days intervals. Kurtzke's Disability Status Scale was evaluated in all the patients together with sum of scores for the neurological functions and the subjective assessment, before and after the treatment. Ten Multiple Sclerosis patients, treated with prednisone (100 mg at alternate days) were taken as a control group. No real advantages were found with the intrathecal treatment as compared to the orally administered steroids.
D000328:Adult; D001812:Blood-Brain Barrier / Q000187:drug effects; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000134:cerebrospinal fluid; D007278:Injections, Spinal; D008297:Male; D008775:Methylprednisolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077555:Methylprednisolone Acetate; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use
D007074:Immunoglobulin G; D000077555:Methylprednisolone Acetate; D011241:Prednisone; D008775:Methylprednisolone